Advertisement
Advertisement
LKFT
Lakefront Biotherapeutics - ADR
29.70
USDSponsored
+0.66
+2.27%
Aug 25, 15:59 UTC -4
Closed
Pre-Market
29.72
+0.02
+0.06%
LKFT Earnings Reports
Positive Surprise Ratio
LKFT beat 2 of 2 last estimates.
100%
Next Report
Date of Next Report
Nov 12, 2026
Estimate for Q3 26 (Revenue/ EPS)
$76.33M
/-$0.43
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-85.99%
Lakefront Biotherapeutics - ADR earnings per share and revenue
On Aug 10, 2026, LKFT reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.43 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 76.33 million, with a --% difference.
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.43 USD, with revenue projected to reach 76.33 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Fate Therapeutics, Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+8.49%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
FAQ
What were Lakefront Biotherapeutics - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Lakefront Biotherapeutics - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Lakefront Biotherapeutics - ADR's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Lakefront Biotherapeutics - ADR expected to report next?
The next earning report is scheduled for Nov 12, 2026.
What are the forecasts for Lakefront Biotherapeutics - ADR's next earnings report?
Based on --
analysts, Lakefront Biotherapeutics - ADR is expected to report EPS of -$0.43 and revenue of $76.33M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement